INDBInternet News Database 2.5 Updated just now · 297 sources Show or hide images Light or dark

Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale

1 source1 article First seen Updated United States Truth score 34

Save Like Comments Compare coverage
Image from Amherst Bee

Summary

Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes

Description from Amherst Bee.

Who is covering this

  1. Amherst Bee Not rated US
    Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale

    Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes

Comments

Comments need JavaScript.